

# **Greg Yanick**

**UI/UX**

# S&P Analyst Web Editor UI

## ▼ Section 1

Section 1A

## ▼ Section 2

Section 2A

Section 2B



PREVIEW

HTML

## Media Release


### Test Title

New York (Standard & Poor's) July 2013

This is the topic about the sector

### Rating Action

Standard & Poor's Ratings Services today issued RATING ACTION.....



### Rationale

#### RATIONALE



**SEI Form PF Dashboard Web Version**

## World Wide Capital

key dates			
2013 Private Equity	4/1	Liquidity Funds Q1	4/15
Private Equity	4/30	Hedge Funds Q1	5/30

### Current Filings

+ New Filing

Filing Period	Type	Number of Funds	Days Remaining	Frequency	Status	Actions		
1Q 2013	Hedge	6	40	Quarterly	Progress	Edit	Export	Review
4Q 2012	Liquidity	3	10	Quarterly	In Review	Edit	Export	File

### Previous Form PF Filings

Filing Period	Type	Number of Funds	Days Remaining	Frequency	Status	Actions		
3Q 2012	Hedge	13	Filed	Annual	Filed	Review		
2Q 2012	Hedge	11	Filed	Annual	Filed	Review		
2Q 2011	Liquidity	12	Filed	Quarterly	Filed	Review		
2Q 2010	Other	10	Filed	Quarterly	Filed	Review		
2Q 2009	Other	10	Filed	Annual	Filed	Review		

**Form PF: September 30,  
2012**

Section 1a    Section 1b    Section 1c    Section 2a    Section 2b    Review    File



You & Related Persons  
Private Funds  
Fund 1 9999901-A  
**Hedge Funds**  
Aggregated Hedge Funds  
Qualifying Hedge Funds

### Section 1c: Information about the hedge funds you advise

Subject to Instruction 5, you must complete a separate Section 1c for each hedge fund that you advise.

#### Item A. Reporting fund identifying information

18. (a) Name of the reporting fund  
 (b) Private fund identification number of the reporting fund


#### Item B. Certain information regarding the reporting fund

19. Does the reporting fund have a single primary investment strategy or multiple strategies?  
 Single primary strategy       Multi-strategy

20. Indicate which of the investment strategies below best describe the reporting fund's strategies. For each strategy that you have selected, provide a good faith estimate of the percentage of the reporting fund's net asset value represented by that strategy. If, in your view, the reporting fund's allocation among strategies is appropriately represented by the percentage of deployed capital, you may also provide that information.  
 (Select the investment strategies that best describe the reporting fund's strategies, even if the descriptions below do not precisely match your characterization of those strategies; select "other" only if a strategy that the reporting fund uses is significantly different from any of the strategies identified below. You may refer to reporting fund's use of these strategies as of the date reporting date or throughout the reporting period, but you must report using the same basis in future filings.)  
 (The strategies listed below are mutually exclusive (i.e., do not report the same assets under multiple strategies). If providing percentages of capital, the total should add up to approximately 100%.)

Strategy	% of NAV (required)	% of capital (optional)
<input type="checkbox"/> Equity, Market Neutral		
<input type="checkbox"/> Equity, Long/Short		
<input type="checkbox"/> Equity, Short Bias		

**SEI Form PF iOS Version**



### Manager Reporting

### Investor Services

### Regulatory Reporting

#### You & Related Persons

##### Private Funds

##### Hedge Funds

##### Aggregated Hedge Funds

##### Qualifying Hedge Funds

Filing Period	Type	Number of F...	Days Remain...	Frequency	Status	Actions
1Q 2013	Hedge	6	40	Quarterly	progress	<a href="#">Edit</a> Export Review
4Q 2012	Liquidity	3	10	Quarterly	In Review	<a href="#">Edit</a> Export File
4Q 2012	Liquidity	3	10	Quarterly	In Review	<a href="#">Edit</a> Export File
4Q 2012	Liquidity	3	10	Quarterly	In Review	<a href="#">Edit</a> Export File

**Abbott Laboratories Data Manager**



Dashboard

Alerts

Test Results

Operators

Devices

QC

My Locations My Devices

## Personnel Group Alpha Dashboard

7 Days

Enter Location

Location A

Location B

Location C

Location C.1

Location C.2

Location C.3


Location C.3.1 ➔

Location C.3.2

Location D

## Test Results Overview

Today 7 Days Month



- 507 Successful
- 96 Invalid Patient ID
- 40 Test Failed
- 5 Repeat Test
- 76 Out of Range
- 0 Other

## Alerts

Test Results

Operators

Devices

QC

## Devices

Total Devices 17

Not Downloaded 0

For Repair 10

LIS ADT

## Operators



## Activity

Recent Customs

- 11:30 AM James Knits performed test on IVIS\_Hem
- 11:40 AM Molly Dolan performed test on IVIS\_GL\_East
- 12:35 PM Jenny Yu performed test on IVIS\_Hem Out of Range



Dashboard

Alerts

Test Results

Operators

Devices

QC

My Locations My Devices

## Personnel Group Alpha Operators

7 Days

Competency Criteria

Cert Competency

Competency Level

Cert Event

Enter Location

Search for  within 

Page 1 of 21 LIS

Location A

Location B

Location C

Location C.1

Location C.2

Location C.3

Location C.3.1

Location C.3.2

Location D

View 1 - 10 of 201

Patient	Patient ID	Panel	Location	Test Time	Operator	Cartridge	Device Model	Result Status	LIS
<input checked="" type="checkbox"/> -	Null	CBC+	Pediatrics	4/3/2012 0:0 AM	Jennifer.Elton	CBC+	null	Null	Null
<input type="checkbox"/> -	52973	EC8+	ER	1/12/2010 6:43 AM	Null	EC8+	null	Null	Null
<input type="checkbox"/> -	2011189	Roche Glucose	ICU	2/10/2010 9:58 AM	Robert.Reids	Roche Glucose	null	Null	Null
<input type="checkbox"/> -	2011190	EC8+	EP	5/9/2010 8:17 AM	Karl.Cooney	EC8+	null	Null	Null
<input type="checkbox"/> -	76009	CBC	ICU	2/3/2010 7:39 AM	Karl.Cooney	CBC+	null	Null	Null
<input type="checkbox"/> -	91659	CBC	CCU	1/13/2010 6:18 AM	Jing.Ho	CBC+	null	Null	Null
<input type="checkbox"/> -	2011192	Roche Glucose	CCU	1/10/2010 2:40 AM	Null	Roche Glucose	null	Null	Null
<input type="checkbox"/> -	14784	Roche Glucose	CCU	6/19/2010 2:53 AM	Robert.Reids	Roche Glucose	null	Null	Null
<input type="checkbox"/> -	2011192	EC8+	GI-East	4/9/2010 8:43 AM	Null	EC8+	null	Null	Null
<input type="checkbox"/> -	75790	CBC	EP	3/10/2010 9:58 AM	Null	CBC+	null	Null	Null

▼

Patient Name: TomRoberts (Patient ID:-)

View by or

Test Result Details Audit Trail

WBC	9.74	10e9/L	MCHC	29.05	TBD	MONO #	0.45	10e9/L
RBC	5.66	10e12/L	RDW	12.71	%CV	EOS #	0.45	10e9/L
HGB	16.63	mmol/L	PLT	360	10e9/L	BASO #	0.15	10e9/L
HCT	50.38	L/L	MPV	8.58	fL/fL	LYM #	2.18	10e9/L
MCV	92.10	fL/fL	NEU #	6.52	10e9/L			
MCH	29.05	fmoL						

Send To LIS Acknowledge



Dashboard

Alerts

Test Results

Operators

Devices

QC

## TEST RESULTS

 Search: Patient Name   Filters   

Patient	Patient ID	Panel	Location	Test Time	Operator	Cartridge	Model	LIS	Excluded
Sarah Jones	2011192	ER	ER	16 Apr 2012 9:50AM	Carol Wang	IVIS	IVIS	Sent	No
Lisa Feder	2011925	CCU	CCU	16 Apr 2012 9:50AM	Ed Johnson	Roche Glucose	Roche Glucose	Sent	No
Sean Jones	2000137	CCU	CCU	16 Apr 2012 9:50AM	Jing Ho	IVIS	IVIS	Sent	No
Henry Feder	4000341	EP	EP	16 Apr 2012 9:50AM	Jing Ho	IVIS	IVIS	Sent	No
George Cooney	2000981	EP	EP	16 Apr 2012 9:50AM	Carol Wang	Roche Glucose	Roche Glucose	Sent	No
Julia Feder	2100187	ER	ER	16 Apr 2012 9:50AM	Carol Wang	IVIS	IVIS	Sent	No
Merideth Sutter	4000341	ER	ER	16 Apr 2012 9:50AM	Ed Johnson	IVIS	IVIS	Sent	No
Sarah Jones	2100187	EP	EP	16 Apr 2012 9:50AM	Jing Ho	IVIS	IVIS	Sent	No
Lisa Feder	4000341	ER	ER	16 Apr 2012 9:50AM	Carol Wang	IVIS	IVIS	Sent	No

## PATIENT DATA

Test Results		Details		Audit Trail
<b>Henry Feder 4000341</b>				
WBC	<b>9.32</b> 10e9/L	3.50		10.50
RBC	<b>5.11</b> 10e12/L	3.90		5.72
HGB	<b>14.86</b> mmol/L	12.00		17.50
HCT	<b>45.01</b> L/L	34.90		50.00
MCV	<b>84.93</b> fL/L	81.20		98.30
MCH	<b>28.87</b> fmol	27.00		31.50
MCHC	<b>28.87</b> TBD	32.00		36.00
RDW	<b>28.08</b> %CV	11.80		15.60
PLT	<b>273</b> 10e9/L	150.00		450.00
MPV	<b>9.37</b> fL/L	7.40		10.40
NEU #	<b>5.77</b> 10e9/L	1.70		7.00
LYM #	<b>2.58</b> 10e9/L	0.90		2.90
MONO #	<b>0.81</b> 10e9/L			
EOS #	<b>0.06</b> 10e9/L			
BAZO #	<b>0.18</b> 10e9/L			



## Dashboard

## Alerts

## Test Results

## Operators

## Devices

## QC

Patient Name



Saved Searches

View 1 - 10 of 201

Patient	Patient ID	Panel	Location	Test Time	Operator	Cartridge	Device Model	Result Status	LIS
<input checked="" type="checkbox"/>	-	Null	CBC+	Pediatrics	4/3/2012 0:0 AM	Jennifer.Elton	CBC+	null	Null
<input type="checkbox"/>	65694	CBC	ER	6/27/2010 8:36 AM	Null	CBC+	null	Null	Null
<input type="checkbox"/>	66141	EC8+	EP	6/25/2010 10:18 AM	Ed.Johnson	EC8+	null	Null	Null
<input type="checkbox"/>	2011189	EC8+	EP	6/25/2010 7:32 AM	Null	EC8+	null	Null	Null
<input type="checkbox"/>	49909	CBC	ICU	6/24/2010 8:53 AM	Null	CBC+	null	Null	Null
<input type="checkbox"/>	75659	EC8+	ER	6/24/2010 7:35 AM	Null	EC8+	null	Null	Null
<input type="checkbox"/>	2011188	Roche Glucose	CCU	6/24/2010 7:29 AM	Ed.Johnson	Roche Glucose	null	Null	Null
<input type="checkbox"/>	93838	EC8+	CCU	6/23/2010 7:3 AM	Robert.Reids	EC8+	null	Null	Null
<input type="checkbox"/>	39048	Roche Glucose	CCU	6/21/2010 10:27 AM	Robert.Reids	Roche Glucose	null	Null	Null
<input type="checkbox"/>	28821	Roche Glucose	ER	6/20/2010 9:41 AM	Null	Roche Glucose	null	Null	Null

Patient Name: TomRoberts (Patient ID:-)

View by or

Test Result Details Audit Trail

WBC	9.74	10e9/L	MCHC	29.05	TBD	MONO #	0.45	10e9/L
RBC	5.66	10e12/L	RDW	12.71	%CV	EOS #	0.45	10e9/L
HGB	16.63	mmol/L	PLT	360	10e9/L	BASO #	0.15	10e9/L
HCT	50.38	U/L	MPV	8.58	fL/L			
MCV	92.10	fL/L	NEU #	6.52	10e9/L			
MCH	29.05	fmoL	LYM #	2.18	10e9/L			

**Send To LIS** **Acknowledge**



## Dashboard

## Alerts

## Test Results

## Operators

## Devices

## QC

Patient Name: Robert Reids

Add



Save Search

View 1 - 10 of 201

Patient	Patient ID	Panel	Location	Test Time	Operator	Cartridge	Device Model	Result Status	LIS
<input checked="" type="checkbox"/>	-	Null	CBC+	Pediatrics	4/3/2012 0:0 AM	Jennifer.Ellon	CBC+	null	Null
<input type="checkbox"/>	65694	CBC	ER	6/27/2010 8:36 AM	Null	CBC+	null	Null	Null
<input type="checkbox"/>	66141	EC8+	EP	6/25/2010 10:18 AM	Ed.Johnson	EC8+	null	Null	Null
<input type="checkbox"/>	2011189	EC8+	EP	6/25/2010 7:32 AM	Null	EC8+	null	Null	Null
<input type="checkbox"/>	49909	CBC	ICU	6/24/2010 8:53 AM	Null	CBC+	null	Null	Null
<input type="checkbox"/>	75659	EC8+	ER	6/24/2010 7:35 AM	Null	EC8+	null	Null	Null
<input type="checkbox"/>	2011188	Roche Glucose	CCU	6/24/2010 7:29 AM	Ed.Johnson	Roche Glucose	null	Null	Null
<input type="checkbox"/>	93838	EC8+	CCU	6/23/2010 7:3 AM	Robert.Reids	EC8+	null	Null	Null
<input type="checkbox"/>	39048	Roche Glucose	CCU	6/21/2010 10:27 AM	Robert.Reids	Roche Glucose	null	Null	Null
<input type="checkbox"/>	28821	Roche Glucose	ER	6/20/2010 9:41 AM	Null	Roche Glucose	null	Null	Null

Page 1 of 21

Patient Name: TomRoberts (Patient ID:-)

View by (L) or (R)

Test Result Details Audit Trail

WBC	9.74	10e9/L	MCHC	29.05	TBD	MONO #	0.45	10e9/L
RBC	5.66	10e12/L	RDW	12.71	%CV	EOS #	0.45	10e9/L
HGB	16.63	mmol/L	PLT	360	10e9/L	BASO #	0.15	10e9/L
HCT	50.38	L/L	MPV	8.58	fL/L			
MCV	92.10	fL/fL	NEU #	6.52	10e9/L			
MCH	29.05	fmoL	LYM #	2.18	10e9/L			

Send To LIS Acknowledge

**Publicis Groupe Project ID8**

id8 is a conversation between the people and  
agencies of....

Search

my agency

id8 global

agencies

calendar

people

jobs



Share something

Favorites

Following

3

Full Name      Date Joined

Agency      Location

Email      Phone

Role/Title      Manager

Expertise      Brands





Interest

My points: 775

Latest points for:



+ track new topic  
or person



I'm tracking:

New York  
Android




web intents  
neuroscience

marathon  
charity

Sam Welch  
ad age

+ track new topic  
or author

bookmarks



# **Publicis Cortex Digital Asset Platform**

**Cortex**

Site Dashboard | Document Library | Members

**Documents**

- All Documents
- I'm Editing
- Others are Editing
- Recently Modified
- Recently Added
- My Favorites

**Library**

**Documents**

**Tags**

New Folder | Upload | Selected Items... | [Edit](#) | [RSS](#)

Select ▾

**Cortex**

Site Dashboard | Document Library | Members | Customize Dashboard | Invite | More ▾

**Site Members**

1 - 1 of 1 | All Members | [Invite](#)

You are the only site member.

 **Gregory Yanick**  
Manager

**Recently Modified Documents**

 [sketch\\_12\\_col.pdf](#)  
Created a minute ago by [Gregory Yanick](#)

 [timeline demo.pdf](#)  
Created a minute ago by [Gregory Yanick](#)

**Site Activities**

Everyone's activities ▾ | all items ▾ | in the last 7 days ▾

**Today**

 [Gregory Yanick](#) added document [timeline demo.pdf](#)  
a minute ago

 [Gregory Yanick](#) added document [sketch\\_12\\_col.pdf](#)  
a minute ago

**Viramune.com Wireframes**

**Banner Image**

Search Patients | Professionals

**Home**

**Patients**

**Profesionals**

Safety  
 FDA

**IMPOR**  
L a s h s h L a s h s h

**Patient Home**

**About VIRAMUNE**

**VIRAMUNE Support**

**Recently Diagnosed**

What is HIV?  
Your Immune System  
Viral Load

**TREATMENT**

**Using VIRAMUNE**

**Links & Resources**

Safety  
 FDA

**Taking VIRAMUNE?**  
Enroll now... ▶

**Banner Image**

Search Patients | Professionals

**Medication Types** When to Start HIV Regimens Avoiding Resistance HCP

Lors! amet Nam sage Nunc hinc

Safety  
 FDA

**Patient Home**

**About VIRAMUNE**

**VIRAMUNE Support**

**Recently Diagnosed**

What is HIV?  
Your Immune System  
Viral Load

**TREATMENT**

**Using VIRAMUNE**

**Links & Resources**

Safety  
 FDA

**Taking VIRAMUNE?**  
Enroll now... ▶

**Banner Image**

Search Patients | Professionals

**Medication Types** When to Start HIV Regimens Avoiding Resistance HCP

Loren! amit Nam sage Nunc hinc

Safety  
 FDA

**Patient Home**

**About VIRAMUNE**

**VIRAMUNE Support**

**Recently Diagnosed**

What is HIV?  
Your Immune System  
Viral Load

**TREATMENT**

**Using VIRAMUNE**

**Links & Resources**

Safety  
 FDA

**Taking VIRAMUNE?**  
Enroll now... ▶

**Banner Image**

Search Patients | Professionals

**Glossary | Email**

**Patient Home**

**About VIRAMUNE**

**VIRAMUNE Support**

**Recently Diagnosed**

What is HIV?  
Your Immune System  
Viral Load

**TREATMENT**

**Using VIRAMUNE**

**Links & Resources**

Safety  
 FDA

**Taking VIRAMUNE?**  
Enroll now... ▶

**Banner Image**

Search Patients | Professionals

**Choosing an**

**IMPORTANT SAFETY II**

**Patient Home**

**About VIRAMUNE**

**VIRAMUNE Support**

**Recently Diagnosed**

What is HIV?  
Your Immune System  
Viral Load

**TREATMENT**

**Using VIRAMUNE**

**Links & Resources**

Safety  
 FDA

**Taking VIRAMUNE?**  
Enroll now... ▶

**Banner Image**

Search Patients | Professionals

**Glossary | Email**

**Avoiding Resistance**

**IMPORTANT SAFETY INFORMATION**

**Patient Home**

**About VIRAMUNE**

**VIRAMUNE Support**

**Recently Diagnosed**

What is HIV?  
Your Immune System  
Viral Load

**TREATMENT**

**Using VIRAMUNE**

**Links & Resources**

Safety  
 FDA

**Taking VIRAMUNE?**  
Enroll now... ▶

**Banner Image**

Search Patients | Professionals

**Ernst & Young ey.com Global**

[https://docs.google.com/present/view?id=dc4m3jb4\\_103fgc3k8gc&revision=\\_latest&start=0&theme=blank&cwj=true](https://docs.google.com/present/view?id=dc4m3jb4_103fgc3k8gc&revision=_latest&start=0&theme=blank&cwj=true)

The presentation slide displays four browser windows side-by-side, illustrating different sections of the Ernst & Young website:

- Top Left Window:** Shows the homepage of Ernst & Young with a large banner image of a sunset over mountains.
- Top Middle Window:** Shows a "Navigation Overlay" where a yellow box highlights the "Services" menu item. The menu includes options like Tax, Assurance, and Advisory.
- Bottom Left Window:** Shows a services page with a sidebar for "Services" and a main content area about "Achieving potential".
- Bottom Right Window:** Shows an "Industry Selector" page with a sidebar for "Industries" and a main content area featuring a "Link to emerging markets" button.

Each window has a blue title bar with the URL "Awareness for Content Publishers 4 Aug 08 V01R01 - Google Chrome" and a blue status bar at the bottom indicating "Google docs" and "Slide 14 of 20".

## Inside page – Sectors

**ERNST & YOUNG**  
Quality is Everything We Do

Home Issues▼ Industries▼ Services▼ Careers▼

Industries ▾ Telecommunications

Email | Print Search

## Making the Telecom connection

What you need to know for the new millennium.

Effective compliance and successful tax function. The telecommunications industry has some of the most networked teams who can effectively tax authority relate.

You can access our telecom industry experts in over 14 countries, are committed to support your tax fi

Talking tax - telecoms transition mature and emerging markets as well as a review of Young's Global Telecommunications and its position on an international basis. Key issues discussed include fixed and location purposes, VAT, transfer pricing, and a survey of 14 countries. Read

ECJ ruling in the Lotte Bellagio case. On 15 May 2000 the European Justice (ECJ) issued its ruling defining the scope of the VAT established in the Marks & Spencer case to other telecommunications. As set out in T201, it may be possible for companies to claim back VAT losses incurred by permanent establishments.

Awareness for Content Publishers 4 Aug 08 V01R01 - Google Chrome

[https://docs.google.com/present/view?&id=dc4m3jb4\\_103fgc3k8g](https://docs.google.com/present/view?&id=dc4m3jb4_103fgc3k8g)

**Inside page –**

**ERNST & YOUNG**  
Quality is Everything We Do

Home Issues▼ Industries▼

Industries ▾ Telecommunications

Sustaining business

Identify the variables that can affect your business.

You can access our telecom industry experts in over 14 countries, are committed to support your tax fi

Effective compliance and successful tax function. The telecommunications industry has some of the most networked teams who can effectively tax authority relate.

Climate change and its implications

EC & Young's climate change strategy is based on the Government's Climate Change Levy Scheme to provide greater incentives for companies to increase energy efficiency and reduce potential for tax increases.

ECJ ruling in the Lotte Bellagio case. On 15 May 2000 the European Justice (ECJ) issued its ruling defining the scope of the VAT established in the Marks & Spencer case to other telecommunications. As set out in T201, it may be possible for companies to claim back VAT losses incurred by permanent establishments.

## Inside page – Issues

**ERNST & YOUNG**  
Quality in Everything We Do

**Home**      **Issues**      **Industries**      **Industries +**      **Sustaining business**

- Driving growth
- Managing risk
- M&A strategies
- Corporate finance
- Enterprise risk
- Information security and privacy
- Internal controls
- Tax authority
- Operational efficiency
- Reporting and governance
- Sustainability
- Transactions

**Change management and its implications**  
Ernst & Young Australia has called on the Government's independent Auditor General to review the implications of the changes to the audit industry. A report will be presented to the Auditor General by 30 June.

**ECI ruling in the Lutje v Justice case**  
On 10 May 2008 the European Court of Justice (ECJ) issued its verdict in the case of Lutje v Justice. The ECJ ruled that the marks 'Lutje' and 'Lutje.com' were not distinctive enough to be registered as trademarks for computer software and electronic commerce establishments. As set out in the ECJ's judgment, the ECJ found that the companies to claim for the legal basis incurred by permanent establishments.

## Inside page – Full article

**ERNST & YOUNG**  
Quality In Everything We Do

**Home**   **Issues**   **Industry**   **Services**   **Tax**   **Careers**

**Business Tax**

**Advisory**  
**Assurance**  
**Business Law**  
**Business Risk**  
**Consulting**  
**Indirect Tax**  
**International**  
**Transactions**  
**Law**  
**Real Estate and Tax**  
**Transactions**  
**Specialty Services**

**Business Tax**

**Business Tax** will only continue to be important if you build it on strong foundations and grow it to a sustainable level. At Ernst & Young, we believe that managing your tax position is just one part of the equation. The other part is how you manage your business. The sum of talented people bring their technical knowledge, business experience and passion to the table — whether you represent us or another firm. — where you are and what services you need.

**Effective compliance and open, transparent reporting are the foundations of a successful tax function.** It's imperative that align with the needs of your business and recognize the potential of change are crucial to sustainability. So we create highly personalized solutions that align with your needs. Consistency and customization and reporting effective tax authority relationships — wherever you operate.

You can access our technical networks across the globe to work with us to reduce inefficiencies, mitigate risk and improve opportunity. Our 22,000 people in over 130 countries, are committed to giving you the quality, consistency and customization you need to support your tax function. If it's Ernst & Young making a difference.

**Effective compliance and open, transparent reporting are the foundations of a successful tax function.** This requires that align with the needs of your business and recognize the potential of change are crucial to sustainability. So we create highly personalized solutions that align with your needs. Consistency and customization and reporting effective tax authority relationships — wherever you operate.

You can access our technical networks across the globe to work with us to reduce inefficiencies, mitigate risk and improve opportunity. Our 22,000 people in over 130 countries, are committed to giving you the quality, consistency and customization you need to support your tax function. If it's Ernst & Young making a difference.

**Related Content:**

**News:**

- [Global tax reform: updated report](#)
- [Consistent tax: hand driven reform](#)
- [Policymakers set up Europe-wide environmental levy to combat climate change](#)
- [Larmer appointed executive vice president of EY](#)
- [Cohen left EY to establish fast lane for women in accounting](#)
- [EY to hire 10,000 new auditors](#)

**EY Contacts:**

- [Shapline and Luhmen](#)
- [Austin Roque and Christopher Ernst](#)
- [Mike Aulbach](#)
- [John C. Doherty](#)
- [The author](#)
- [Sue Kunkel](#)
- [Dawn L. Johnson](#)
- [Deborah M. Lerner](#)
- [Jeffrey M. Lerner](#)
- [Karen McGrath](#)
- [Mike Murphy](#)

**Library** | **EY Investor** | **E-mail** | **Print** | **Search** | **United States - Change**


**The Importance of taxonomy and tagging**

---

**Scenario:** UK member firm pushes content to sub-service line 'Capital Markets'. Current state taxonomy can be customised for local market needs.

**Issue:** The new approved Universal taxonomy may not include 'Capital Markets'

**Resulting Action:** You will need to work with your Stakeholder to negotiate content items according to the new taxonomy.



The screenshot shows a website interface with a navigation bar at the top. Below the navigation bar, there is a large image of a building's steel framework. A yellow arrow points from the word 'Transactions' in the navigation menu to the 'Capital Markets' item in the taxonomy diagram. The taxonomy diagram shows 'Services' branching into 'Advisory' and 'Assurance', each with a list of sub-items.

Perspectives	Services	Industries	About us	Media	Alumni	Careers
Global Home > UK	Overview					
	Assurance and Advisory >	Overview				
	Strategic Growth Markets >	Assurance				
	Tax >	Business Advisory Services				
	Transactions	Capital Markets				
		Corporate Responsibility Services				
		Financial Reporting				
		Pensions Services				
		Risk Advisory Services >				

```
graph LR; Services[Services] --> Advisory[Advisory]; Services --> Assurance[Assurance];
```

About Advisory
Our services
Actuarial
Business advisory
Business risk
Financial services risk management
Fraud investigation and dispute
Technology and security risk
About Assurance
Accounting
Audit
Key performance indicators
Technology and security risk
Sustainability assurance and advisory

**Ernst & Young US Assurance Prototypes**

**Assurance and Advisory**

Welcome John Smith! United States

My Profile | EY.com | EY Online | Contact EY Concierge

**ERNST & YOUNG**  
Quality In Everything We Do

Home

**Publications**

Featured + Lorem + Lorem + Lorem

Assurance and Advi...  
test.  
test.

1 2 3 4

**Global News**

<< Previous 3 of 9 Next >>

Lorem ipsum dolor sit amet, consectetur adipisicing elit sed do eiusmod tempor incididunt ut labore et dolore. [Learn more](#)

Lorem ipsum dolor sit amet, consectetur adipisicing elit sed do eiusmod tempor incididunt ut labore et dolore. [Learn more](#)

Lorem ipsum dolor sit amet, consectetur adipisicing elit sed do eiusmod tempor incididunt ut labore et dolore. [Learn more](#)

eiusmod tempor incididunt ut labore et dolore. [Learn more](#)

Lorem ipsum dolor sit amet, consectetur adipisicing elit sed do eiusmod tempor incididunt ut labore et dolore. [Learn more](#)

Lorem ipsum dolor sit amet, consectetur adipisicing elit sed do eiusmod tempor incididunt ut labore et dolore. [Learn more](#)

Lorem ipsum dolor sit amet, consectetur adipisicing elit sed do eiusmod tempor incididunt ut labore et dolore. [Learn more](#)

Ut enim ad minim

Veniam quis nostrum

Suscipit labore nosam

Ut enim ad minim

Veniam quis nostrum

Suscipit labore nosam

**Select Areas of Interest**

Set Areas of Interest

By Location

- Asset Management
- Automotive
- Banking & Capital Markets
- Biotechnology
- Consumer Products
- Insurance
- Media & Entertainment
- Mining & Metals
- Oil & Gas
- Pharmaceutical

By Industry

- >Lorem ipsum
- >Lorem ipsum
- Lorem ipsum

View:

OK Cancel

Download Email Print

My Profile | EY.com | EY Online | Contact EY Concierge

Go Select Areas of Interest

Loremi + Loremi + Loremi

View:

1 2 3 4

Related News

- Ut enim ad minim
- Veniam quis nostrum
- Suscipit labore nosam
- Ut enim ad minim
- Veniam quis nostrum
- Suscipit labore nosam


Related Publications

- Ut enim ad minim
- Veniam quis nostrum
- Suscipit labore nosam
- Ut enim ad minim
- Veniam quis nostrum
- Suscipit labore nosam

Recently Viewed

- Ut enim ad minim
- Veniam quis nostrum

**Ernst & Young Chile**



Ernst & Young y DP Conference: La nueva Justicia Laboral

El comienzo de funcionamiento de los nuevos tribunales laborales en la Región Metropolitana y los cambios que provocará en los litigios de esta índole son una de las preocupaciones de las empresas durante este año.

En Agenda

La nueva Justicia Laboral

Fecha: 10 de agosto de 2009  
Lugar: Hotel Río Carlton Santiago  
Dirección: ...

Lanzamiento del Centro de Gobierno Corporativo y Estratégico

Fecha: 16 de agosto de 2009  
Lugar: Universidad Adolfo Ibáñez, sede...

Programa Finanzas para la Alta Dirección

Fecha: Medio y fines de mes al 18 de agosto al 19 de septiembre  
Lugares: ...

Regístrate en Ernst & Young Online | Archivos | Quienes somos | Prensa

Nuestros Servicios



Auditores y Asesores de Negocios

Contamos con equipos de profesionales capacitados para atender los distintos sectores productivos del mercado.



**ERNST & YOUNG**

Quality In Everything We Do

Inicio

Temas de interés | Industrias | Servicios | Carreras

Inicio

Chile (Español) - Cambiar

Buscar en todo ey.com

Chile (Español)

Buscar en todo ey.com

Ernst & Young Online

Nombre de usuario:  
Clave.:

Aprenda más  
Olvidó su nombre de usuario o clave.

Oportunidades en la adversidad: acelerando el cambio

¿Cómo está respondiendo su compañía a la crisis? Consultamos a más de 550 ejecutivos en todo el mundo - conozca los resultados.



Oportunidades ante la adversidad



IFRS- Instrumentos financieros



Aumentando la flexibilidad a través del Outsourcing

Servicios

Reunimos al equipo multidisciplinario adecuado para su negocio, proveniente de nuestro acervo global de talentos, a fin de ofrecerle servicios de calidad que le ayuden a alcanzar su potencial.

Conozca más acerca de:

- Auditoría
- Asesoría
- Impuestos
- Transacciones

Industrias

Los Centros Globales por Industria establecidos alrededor del mundo, han sido diseñados para ofrecerle una clara perspectiva de los temas presentes y futuros que a usted más le interesan.

Descubra más sobre su industria.

Carreras

Mantenemos nuestro compromiso de apoyar a nuestra gente a lograr su potencial.

Consulta las oportunidades más recientes para:

- Estudiantes
- Profesionales
- Ejecutivos

Nuestras Oficinas

